Brief: Biomerieux H1 Operating Income Down At EUR 208 Million

Biomerieux SA

01/09/2023 06:11

Sept 1 (Reuters) - Biomerieux SA  BIOX.PA :
    * €1,770 MILLION IN FIRST-HALF 2023 SALES, UP 8.3%
LIKE-FOR-LIKE
    * Q2 SALES ORGANIC GROWTH AT 9.2% DRIVEN BY A STRONG
MOMENTUM IN
CLINICAL  MICROBIOLOGY (+18%)
    * THE GROUP ENDED THE FIRST-HALF 2023 WITH AN OPERATING
INCOME OF
€208 MILLION, DOWN 30%
    * OUTLOOK: CONFIRMS THE 2023 FULL YEAR GUIDANCE RELEASED IN
MARCH
FOR BOTH SALES AND CONTRIBUTIVE OPERATING INCOME BEFORE
NON-RECURRING ITEMS
    * OUTLOOK: SALES GROWTH FOR 2023 IS EXPECTED TO REACH +8% TO
+10%
AT CONSTANT EXCHANGE RATES AND SCOPE OF CONSOLIDATION
    * DIVIDEND OF €100 MILLION HAS BEEN PAID IN FIRST-HALF 2023,
TO BE
COMPARED WITH €101 MILLION IN 2022
    * OUTLOOK 2023: CONTRIBUTIVE OPERATING INCOME BEFORE
NON-RECURRING
ITEMS SHOULD BE IN A RANGE OF €600 MILLION TO €630 MILLION

Further company coverage:  BIOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))